David F. Townson

- Lead organization's mission to deliver curative treatments for Hemophilia and Oncology - Member, Board of Directors

Led Global Immuno-Oncology, Cell Therapy, and Precision Medicine Portfolio: - Partner Globally: Build and Lead Highly Engaged Global Teams of Dedicated Experts - Optimize Development: Deliver Innovative Treatments to Patients Faster: VITRAKVI®, HYRNUO® - Define and Execute Strategy: Maximize Benefit to Patients and Ensure Shareholder Value

Head of Chimeric Antigen Receptor T-Cell (CART) Program Management Office | Immunotherapy | Cell and Gene Therapy Unit. KYMRIAH® - Partnered with a dedicated team of professionals committed to bringing hope to cancer patients and their families: We never give up because patients are counting on us. - Created a culture of transparency, collaboration, and communication in order to accelerate the delivery of new products: One Team Working Together. - Challenged standard practice to drive innovative thinking: Do what it takes to get the product in patient's hands without comprising safety or integrity. - Removed organizational obstacles: Built an environment where teams had the freedom to operate and focus on what is most important - our patients.

• Seamless Integration: Strategy and Operations for Global Oncology / Hematology and Sickle Cell Disease • Passionate Delivery: JADENU® submissions & approvals delivered ahead of schedule. Anti-p selectin for Sickle Cell Disease: ADAKVEO® • Professional Leadership: Program Management Function Head for 14 US-Based Staff. EXJADE®, JADENU®, ADAKVEO®

Senior Vice President, Development • Created culture where team members took personal ownership of the organization’s product success • Aligned decision processes to ensure all assets had the resources to deliver our aggressive objectives • Led governance to address emerging issues and support programs delivering on-time and on-budget

Vice President Development, Project Management Project Leader, Diabetes • Led diabetes drug-device program through development and company's first NDA submission. • Integrated People/Process/Tools to improve project delivery via value-based decision making. • Partnered with Business Development staff and led due diligence teams for R&D opportunities. AFREZZA®

Worldwide Portfolio Director: CVMED (cardiovascular and metabolic disease) & Ophthalmology pipelines • Increased productivity of the cardiovascular, metabolic, and endocrine disease portfolio. • Managed global resource strategy to achieve optimal delivery of all R&D assets. • Led integration of Pharmacia portfolio into Pfizer quickly and effectively before & after acquisition. • Served as Subject Matter Expert for portfolio management discipline internally and externally. • Developed Processes, Tools, and Behaviors necessary to drive portfolio centered decisions.

Global Project Leader, Diabetes and Ophthalmology: • Led global development teams in Diabetes (inhaled insulin) and Ophthalmology.(VEGF inhibitor) • Led global alliance teams and R&D due diligence assessment and asset integration teams. • Awarded Research & Development "Project Team of the Year". • EXUBERA®, MACUGEN®

Chef de Projet / Global Project Leader, Vaccines: • Led vaccine development programs for global markets: Meningitis, Avian Flu, Rabies • Served as Alliance Leader for small EU Biotechnology companies while based in France. • Developed portfolio prioritization methodologies for strategic planning. • MENACTRA®

R&D Project Manager, Early Development: • Managed early stage drug and device product development teams: Asthma and COPD. • COMBIVENT® Unit Dose Vials, ATROVENT® HFA Scientist II: • Supported early development projects via formulation development support, validation, etc. • VIRAMUNE®.